ASGCT is pleased to be at the #NORDSummit this week! Stop by our booth to connect with our patient education resources (including our new coloring book!) and discuss the latest policies affecting rare disease research and individuals. @RareDiseases

The 2026 Breakthroughs abstracts are now live! Get a preview of the latest research and scientific advancements being presented at #ASGCTBreakthroughs, happening Nov. 12-13 in Nashville and virtually. There's still time to register and join experts from across the cell and gene therapy field as they share emerging research, innovative approaches and new developments shaping the future of CGT. Explore the abstracts and register today: asgct.org/breakthroughs

Congratulations to the 9 ASGCT members elected to the @theNAMedicine! Their pioneering research and clinical leadership continue to drive progress in cell and gene therapy and improve patient outcomes around the globe. We're proud to celebrate this outstanding achievement. #ASGCT #GeneTherapy #CellTherapy

Hot off the press! 📢 Our Q3 2026 Gene, Cell and RNA Therapy Landscape Report, developed with Citeline, is here. Explore seven new approvals, an expanding clinical pipeline and the latest advancements shaping the field. Read more: bit.ly/4ufliLp #ASGCT #CGT

One month to go until a full day of Safety, Translation, and Real-World Implementation of AAV and LNP Gene Therapies. On Nov. 20, ASGCT and the Clinical In Vivo Gene Therapy group at Children’s Hospital of Philadelphia are bringing experts together to explore the safety, translation and real-world implementation of AAV and LNP in vivo gene therapies. Hear practical insights from experts working across clinical and translational settings, explore considerations that span specialties and earn CME credit along the way. Save your seat: bit.ly/4uK4PPz

⚠️@NIH_OSP is seeking input on a proposed biosafety policy that could affect #CGT research, including definitions of genetic modifications and oversight of existing research practices. Help inform clear, risk-based requirements. Comments are due Oct 19:  bit.ly/3SRMvH8 #ASGCTadvocacy

On-demand access to our 2026 Policy Summit is now available! Catch up on the conversations you missed or rewatch your favorite sessions. Access on-demand now ➡️ asgct.org/events-meetings/20…

New research partnership! 🧬 ASGCT and the National Tay-Sachs & Allied Diseases Association (NTSAD) are launching the inaugural NTSAD-ASGCT Translational Research Fellowship Program to help advance innovative genetic medicine research for rare neurogenetic diseases. The fellowship will provide $50,000 per year for up to two years to support research focused on Tay-Sachs, Sandhoff, GM1 gangliosidosis or Canavan disease, with the goal of moving promising discoveries closer to clinical application. Learn more about the fellowship, eligibility criteria and application deadlines: bit.ly/4hciETk Help us spread the word by sharing this opportunity with individuals working to advance new therapies for rare neurogenetic diseases. #ASGCT #RareDisease #GeneTherapy #CellTherapy #TaySachs #Sandhoff #GM1 #CanavanDisease #RareDiseaseResearch

When knowledge is shared across sectors, the rare disease community can find answers faster and close gaps in care and access. Join the 2026 NORD Breakthrough Summit, Oct. 25–27 in Washington, DC, to exchange ideas and build new connections. ASGCT staff will be there to connect you with patient education resources (including our new coloring book!), and discuss the latest policies affecting rare disease research and individuals. Learn more ➡️ nordsummit.org #NORDSummit #RareDisease

🔬 Don't wait for the Annual Meeting to share your latest science! Submit your late-breaking abstract for Breakthroughs in Cell + Gene Therapy by Monday, October 12, 2026. Learn more and submit now ➡️ bit.ly/4wHH10l

How do breakthrough cell and gene therapies actually reach patients? Sara Johnson Davis joins The Issue Podcast this month to discuss the growing role of patient advocacy in drug development, lessons from the sickle cell community, and the key barriers to access. Listen now ➡️ bit.ly/4xW4njt

It was a successful day of meaningful collaboration and conversation at today’s Policy Summit in Washington, D.C.! The day's engagement reinforced the importance of our field coming together to drive progress for patients and the broader healthcare community. Thank you to all our speakers, attendees, and partners for making the event impactful! If you missed us today, you can watch all of today's sessions on demand, available soon. bit.ly/4wIMIem #PS26 #ASGCTadvocacy

Submit an abstract to the Inaugural Canadian Gene and Cell Therapy Conference by October 1! Early-career investigators and trainees are invited to submit abstracts highlighting advances across the cell and gene therapy landscape from basic discovery through to clinical implementation. Accepted abstracts will be presented as posters, with selected submissions invited for short oral presentations. For more information or to submit an abstract, visit cancgt.ca.

ASGCT appreciates Congress acting through the bipartisan CR to pause OMB’s proposed Uniform Guidance changes. Thank you also to @RepLaLota, @RepGarbarino, and @RepDonBacon for speaking out for a fair, transparent federal funding process. ➡️ Read their letter here: bit.ly/4gQ9IkT

📢 We're less than one week away from the 2026 Policy Summit! Join us for a full day of high-impact discussions across regulatory, manufacturing, access, and innovation in CGT. Can't make it in person? Attend virtually to get access to the same critical conversations from anywhere, plus the convenience of 30-day on-demand viewing after the event. Register now ➡️ bit.ly/4wIMIem #ASGCTadvocacy #PS26

ASGCT is urging HHS OIG to establish clearer protections for clinical trial participant support, including a safe harbor for reasonable participation-related costs, reducing barriers to research while preserving patient safeguards. Read more: bit.ly/4h2FTyU #ASGCTadvocacy

The FDA has approved Genglycos (pariglasgene brecaparvovec), an AAV gene therapy developed by Ultragenyx Pharmaceuticals, for treatment of Glycogen Storage Disease Type Ia (GSDIa) in patients 8 years of age and older with a documented history of hypoglycemia requiring intensive dietary management. This approval marks the first approved therapy of its kind for individuals born with GSDIa. Read our full blog post about the approval here: bit.ly/3SbpDlN

📰 Our latest edition of The Patient Press newsletter is now available! This month, read updates about OMB, check out our two new Patient Education resources, catch up on our recent Congressional Briefing on CGT for Rare Disease, and more. Read The Patient Press now ➡️ bit.ly/4il1BiC

Register now for ASGCT's 2026 Policy Summit - September 14, in Washington DC and online! Newly announced: Grace Graham of the Office of Policy, Legislation, and International Affairs, FDA will be speaking about the future of CGT regulation. Plus, FDA CBER's Dr. Andrew Byrnes and Dr. Kimberly Schultz will speak to address some of the CGT field's most pressing regulatory questions. Register to join the conversation today: bit.ly/4wIMIem #ASGCTadvocacy #PS26

The August edition of The Advocate newsletter is now available! See updates on federal funding negotiations, view ASGCT's recent congressional briefing on gene therapy for ultrarare and N-of-1 diseases, check out who's speaking at the 2026 Policy Summit, and more. Read now ➡️ bit.ly/4bFDzek #ASGCTadvocacy #CGT